Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Testicular differentiation factor SF-1 is required for human spleen development
David Zangen, … , Paul Renbaum, Ephrat Levy-Lahad
David Zangen, … , Paul Renbaum, Ephrat Levy-Lahad
Published April 8, 2014
Citation Information: J Clin Invest. 2014;124(5):2071-2075. https://doi.org/10.1172/JCI73186.
View: Text | PDF
Brief Report Genetics

Testicular differentiation factor SF-1 is required for human spleen development

  • Text
  • PDF
Abstract

The transcription factor steroidogenic factor 1 (SF-1; also known as NR5A1) is a crucial mediator of both steroidogenic and nonsteroidogenic tissue differentiation. Mutations within SF1 underlie different disorders of sexual development (DSD), including sex reversal, spermatogenic failure, ovarian insufficiency, and adrenocortical deficiency. Here, we identified a recessive mutation within SF1 that resulted in a substitution of arginine to glutamine at codon 103 (R103Q) in a child with both severe 46,XY-DSD and asplenia. The R103Q mutation decreased SF-1 transactivation of TLX1, a transcription factor that has been shown to be essential for murine spleen development. Additionally, the SF1 R103Q mutation impaired activation of steroidogenic genes, without affecting synergistic SF-1 and sex-determining region Y (SRY) coactivation of the testis development gene SOX9. Together, our data provide evidence that SF-1 is required for spleen development in humans via transactivation of TLX1 and that mutations that only impair steroidogenesis, without altering the SF1/SRY transactivation of SOX9, can lead to 46,XY-DSD.

Authors

David Zangen, Yotam Kaufman, Ehud Banne, Ariella Weinberg-Shukron, Abdulsalam Abulibdeh, Benjamin P. Garfinkel, Dima Dweik, Moein Kanaan, Núria Camats, Christa Flück, Paul Renbaum, Ephrat Levy-Lahad

×

Figure 3

Functional studies of the SF1 R103Q mutant.

Options: View larger image (or click on image) Download as PowerPoint
Functional studies of the SF1 R103Q mutant.
 
Transcriptional activation...
Transcriptional activation of spleen-specific (A), testes-specific (B), and steroidogenic (C) promoters by WT or mutant SF1 expression vectors were assayed by transient cotransfection of the expression vectors using the Promega Dual Luciferase assay system. For SF-1 binding elements in the reporters, see Supplemental Table 3. (A) Transcriptional activation of the spleen development–specific TLX1 promoter by WT and mutant SF1 constructs was studied in COS-7 cells. Ve, empty vector control. The TLX1 promoter–luciferase reporter construct is shown below, with the TLX1 promoter, transcription start site (arrow), exon 1 harboring 2 SF-1 binding sequences (spheres), and the luciferase reporter gene (Luc). Numbering is relative to the TLX1 transcription start site, at position +1. (B) Activity of the SOX9 testis-specific TESCO-luciferase enhancer, harboring both SF-1 and SRY/SOX binding sites, was measured in COS-7 cells. Transfections were performed using empty vector control (–) or WT or mutant SF1 expression vectors, either alone or together with Sry-myc or Sox9 expression vectors (3). A schematic illustration of the reporter construct is shown below. (C) Activity of the steroidogenic CYP11A1 (left), CYP17A1 (middle), and HSD3B2 (right) promoter reporter constructs (27) transfected with the SF1 constructs into nonsteroidogenic HEK293 cells. Results represent mean ± SEM relative luciferase activity of 4–5 independent experiments performed in duplicate. *P < 0.05, **P < 0.01, ***P < 0.001 vs. WT.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts